Company intelligence / Profile preview

Tolerance Therapeutics

Ownership: Private
Development stage: Other

Overview

Tolerance Therapeutics was a holding company for a royalty interest in TZIELD (teplizumab), the first disease-modifying monoclonal antibody therapy approved to delay onset of Stage 3 type 1 diabetes. The drug is marketed by Sanofi and has shown efficacy in slowing the decline of C-peptide levels in children and adolescents with newly diagnosed disease.

Therapeutic areas: Endocrinology
Modalities: Monoclonal antibody
Industry: Investors

Partnerships

Sanofi

Beyond the preview

Go deeper on Tolerance Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tolerance Therapeutics.

Explore the full profile